267 related articles for article (PubMed ID: 26699397)
1. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.
Zent CS; Bowen DA; Conte MJ; LaPlant BR; Call TG
Leuk Lymphoma; 2016 Jul; 57(7):1585-91. PubMed ID: 26699397
[TBL] [Abstract][Full Text] [Related]
2. Chemoimmunotherapy for relapsed/refractory and progressive 17p13-deleted chronic lymphocytic leukemia (CLL) combining pentostatin, alemtuzumab, and low-dose rituximab is effective and tolerable and limits loss of CD20 expression by circulating CLL cells.
Zent CS; Taylor RP; Lindorfer MA; Beum PV; LaPlant B; Wu W; Call TG; Bowen DA; Conte MJ; Frederick LA; Link BK; Blackwell SE; Veeramani S; Baig NA; Viswanatha DS; Weiner GJ; Witzig TE
Am J Hematol; 2014 Jul; 89(7):757-65. PubMed ID: 24723493
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.
Brown JR; Messmer B; Werner L; Davids MS; Mikler E; Supko JG; Fisher DC; LaCasce AS; Armand P; Jacobsen E; Dalton V; Tesar B; Fernandes SM; McDonough S; Ritz J; Rassenti L; Kipps TJ; Neuberg D; Freedman AS
Haematologica; 2013 Jun; 98(6):964-70. PubMed ID: 23645694
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Trial of Fludarabine Combined With Subcutaneous Alemtuzumab for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia.
Flowers CR; Brown JR; Rosenthal H; Stock W; Katzen HI; Cohen JB; Sinha R; Lakhanpal S; Leis JF; Waller EK; Jaye DL
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):694-8. PubMed ID: 26385641
[TBL] [Abstract][Full Text] [Related]
6. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation.
Zent CS; LaPlant BR; Johnston PB; Call TG; Habermann TM; Micallef IN; Witzig TE
Cancer; 2010 May; 116(9):2201-7. PubMed ID: 20166206
[TBL] [Abstract][Full Text] [Related]
7. Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience.
Sciumè M; Vincenti D; Reda G; Orofino N; Cassin R; Giannarelli D; Gaidano G; Rossi D; Cortelezzi A
Am J Hematol; 2015 Nov; 90(11):970-4. PubMed ID: 26201283
[TBL] [Abstract][Full Text] [Related]
8. Akt inhibitor MK-2206 in combination with bendamustine and rituximab in relapsed or refractory chronic lymphocytic leukemia: Results from the N1087 alliance study.
Larsen JT; Shanafelt TD; Leis JF; LaPlant B; Call T; Pettinger A; Hanson C; Erlichman C; Habermann TM; Reeder C; Nikcevich D; Bowen D; Conte M; Boysen J; Secreto C; Lesnick C; Tschumper R; Jelinek D; Kay NE; Ding W
Am J Hematol; 2017 Aug; 92(8):759-763. PubMed ID: 28402581
[TBL] [Abstract][Full Text] [Related]
9. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
10. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
[TBL] [Abstract][Full Text] [Related]
11. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
[TBL] [Abstract][Full Text] [Related]
12. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study.
Seymour JF; Ma S; Brander DM; Choi MY; Barrientos J; Davids MS; Anderson MA; Beaven AW; Rosen ST; Tam CS; Prine B; Agarwal SK; Munasinghe W; Zhu M; Lash LL; Desai M; Cerri E; Verdugo M; Kim SY; Humerickhouse RA; Gordon GB; Kipps TJ; Roberts AW
Lancet Oncol; 2017 Feb; 18(2):230-240. PubMed ID: 28089635
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies.
Awan FT; Gore L; Gao L; Sharma J; Lager J; Costa LJ
Br J Haematol; 2016 Oct; 175(1):55-65. PubMed ID: 27293194
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
17. Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).
Kempin S; Sun Z; Kay NE; Paietta EM; Mazza JJ; Ketterling RP; Frankfurt O; Claxton DF; Saltzman JN; Srkalovic G; Callander NS; Gross G; Tallman MS
Acta Haematol; 2019; 142(4):224-232. PubMed ID: 31336367
[TBL] [Abstract][Full Text] [Related]
18. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial.
Elter T; Borchmann P; Schulz H; Reiser M; Trelle S; Schnell R; Jensen M; Staib P; Schinköthe T; Stützer H; Rech J; Gramatzki M; Aulitzky W; Hasan I; Josting A; Hallek M; Engert A
J Clin Oncol; 2005 Oct; 23(28):7024-31. PubMed ID: 16145065
[TBL] [Abstract][Full Text] [Related]
19. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
[TBL] [Abstract][Full Text] [Related]
20. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]